PBA
ARVN icon

Paradigm Biocapital Advisors’s Arvinas ARVN Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ARVN Stock Details ARVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,339,961
Closed -$57.6M – 30
2024
Q3 		$57.6M Sell
2,339,961
-98,188
-4% -$2.56M 1.95% 16
2024
Q2 		$64.9M Sell
2,438,149
-176,786
-7% -$5.63M 2.48% 16
2024
Q1 		$108M Buy
2,614,935
+1,683,632
+181% +$73.6M 3.8% 9
2023
Q4 		$38.3M Buy
+931,303
New +$21.8M 1.79% 18
2023
Q1 		– Sell
-599,599
Closed -$20.5M – 27
2022
Q4 		$20.5M Buy
599,599
+315,822
+111% +$13.3M 2.41% 18
2022
Q3 		$12.6M Sell
283,777
-233,629
-45% -$11.3M 1.68% 19
2022
Q2 		$21.8M Buy
517,406
+26,073
+5% +$1.31M 4.34% 10
2022
Q1 		$33.1M Buy
491,333
+222,814
+83% +$15.2M 8.74% 3
2021
Q4 		$22.1M Buy
+268,519
New +$21.9M 6.3% 7

Other funds holding ARVN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Paradigm Biocapital Advisors's ARVN Position: Q4 2024 in Review

Paradigm Biocapital Advisors sold out of Arvinas (ARVN) in Q4 2024, closing a stake of 2,339,961 shares — an estimated $57.6M sold.

Paradigm Biocapital Advisors first reported a position in ARVN in Q4 2021 and held it in 9 quarters. The position peaked at $108M in Q1 2024. 198 funds tracked by Wall St. Rank hold ARVN as of Q4 2024.

  • Paradigm Biocapital Advisors reported no remaining Arvinas position as of Q4 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 2,339,961 Arvinas shares in Q4 2024, an estimated $57.6M.
  • Paradigm Biocapital Advisors first reported a position in Arvinas in Q4 2021 and held it in 9 quarters.
  • Paradigm Biocapital Advisors's Arvinas position peaked at $108M in Q1 2024.
  • 198 funds tracked by Wall St. Rank held Arvinas as of Q4 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.